drugset
drugset / Trial / NCT07349589

Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers

NCT07349589 ↗

Phase 1 Not yet recruiting 48 enrolled Daewon Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5524 in healthy adult volunteers.

Timeline

Start
2026-02-01
Primary completion
2026-02-28
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DW5524 Unknown — —
Subject DW5524-A Unknown — —

Indications

No indication recorded.